WELBIO is an inter-university life sciences research institute based in Wallonia, Belgium. WELBIO aims at promoting scientific excellence in fundamental life sciences research and translating scientific achievements in medical, pharmaceutical and veterinary biotechnology applications.
WELBIO is pleased to announce a “Bridge grant” has been awarded to Professor Pierre van der Bruggen, Principal Investigator at the de Duve Institute (Université Catholoque de Louvain). The WELBIO Bridge fund is intended for WELBIO investigators and designed to bridge the gap between early stage research and the valorisation of the research findings (patent application, technology transfer, applied research project).
In a study published in Nature, researchers led by Pr. Cédric Blanpain, MD/PhD, WELBIO investigator, and Professor at the Université Libre de Bruxelles, in collaboration with Pr. Benjamin D Simons, University of Cambridge,UK, demonstrated that the capacity of oncogene-expressing cells to induce tumor formation depends on the clonal dynamics of the cancer cell of origin.
Twenty-two WELBIO research programmes are currently supported through the Fund for Strategic Fundamental Research (F.R.S. (Fonds de la Recherche Scientifique) [Fund for Scientific Research]-FNRS), within three universities of the Wallonia-Brussels Federation. The WELBIO researchers conduct innovative research in various areas such as cancer biology, neurobiology, immunology, genetics, development biology, metabolism or microbiology. Their scientific discoveries may lead to the development of new medicines, treatments or diagnoses (e.g. cancer, neuropsychiatric, metabolic or inflammatory diseases, neurodegenerative disorders, antibiotic resistance) as well as to biotechnology applications.